ChinaBio Today -- Most of the stories emanating from the world of China life science had to do with the business side of the segment: an IPO, a possible takeover, new capital and earnings – lots of earnings. In addition, there were cross-border deals that will introduce new products to China and China products to the rest of the world, plus new product approvals and China-France collaborative research.
